{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:16:47Z","timestamp":1767241007022,"version":"3.48.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.04.024","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T11:34:30Z","timestamp":1701430470000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A discrete choice experiment to quantify the influence of trial features on the decision to participate in cystic fibrosis trials"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0988","authenticated-orcid":false,"given":"Rebecca","family":"Dobra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1199","authenticated-orcid":false,"given":"Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Madge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.04.024_bib0001","unstructured":"Involve patients, NIHR [Internet]. [cited 2020 Aug 29]. Available from: https:\/\/www.nihr.ac.uk\/health-and-care-professionals\/engagement-and-participation-in-research\/involve-patients.htm."},{"key":"10.1016\/j.jcf.2023.04.024_bib0002","unstructured":"Cystic Fibrosis Trust - Announcing the new clinical trials accelerator platform! [Internet]. [cited 2018 Mar 14]. Available from: https:\/\/www.cysticfibrosis.org.uk\/news\/announcing-the-new-clinical-trials-accelerator-platform."},{"issue":"4","key":"10.1016\/j.jcf.2023.04.024_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/intqhc\/10.4.319","article-title":"Patient satisfaction with clinical trial participation","volume":"10","author":"Verheggen","year":"1998","journal-title":"Int J Qual Health Care"},{"issue":"22","key":"10.1016\/j.jcf.2023.04.024_bib0004","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jcf.2023.04.024_bib0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40615-016-0285-1","article-title":"Racial differences among factors associated with participation in clinical research trials","volume":"4","author":"Kurt","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"issue":"4546","key":"10.1016\/j.jcf.2023.04.024_bib0006","doi-asserted-by":"crossref","first-page":"w14556","DOI":"10.4414\/smw.2017.14556","article-title":"Insufficient recruitment and premature discontinuation of clinical trials in Switzerland: qualitative study with trialists and other stakeholders","volume":"147","author":"Briel","year":"2017","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.024_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jada.2003.10.014","article-title":"Successful recruitment and retention strategies for a randomized weight management trial for people with diabetes living in rural, medically underserved counties of South Carolina: the POWER study","volume":"104","author":"Parra-Medina","year":"2004","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jcf.2023.04.024_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.conctc.2016.01.002","article-title":"Factors affecting patient participation in clinical trials in Ireland: a narrative review","volume":"3","author":"Walsh","year":"2016","journal-title":"Contemp Clin Trials Commun"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.024_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/jme.26.2.126","article-title":"Paying research subjects: participants\u2019 perspectives","volume":"26","author":"Russell","year":"2000","journal-title":"J Med Ethics"},{"issue":"5","key":"10.1016\/j.jcf.2023.04.024_bib0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/PEC.0000000000000368","article-title":"Factors associated with participation in research conducted in a pediatric emergency department","volume":"31","author":"Taylor","year":"2015","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.024_bib0011","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1533317511423020","article-title":"African American participation in Alzheimer's disease research that includes brain donation","volume":"26","author":"Darnell","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.jcf.2023.04.024_bib0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1569-1993(11)60010-6","article-title":"Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society\u00e2\u20ac\u201cClinical Trials Network (ECFS-CTN)","volume":"10","author":"De Boeck","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.024_bib0013","series-title":"Thorax, British Thoracic Society Winter Meeting, The Queen Elizabeth II Centre Broad Sanctuary Westminster London SW1P 3EE 2 to 4 December 2015 Programme and Abstracts [Internet]","article-title":"Understanding and improving participants\u2019 experience of health research; Patient evaluation of research participation in a dedicated respiratory biomedical reserach unit (BRU) Clinical resreach facility (CRF)","author":"Dobra","year":"2017"},{"key":"10.1016\/j.jcf.2023.04.024_bib0014","doi-asserted-by":"crossref","unstructured":"Dobra R, Elborn S, Madge S, Allen L, Saunders C, Goundry S, et\u00a0al. P361 What influences participation in clinical trials by people with cystic fibrosis? A National Delphi Study. 2020.","DOI":"10.1016\/S1569-1993(20)30689-5"},{"issue":"11","key":"10.1016\/j.jcf.2023.04.024_bib0015","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jpain.2016.07.008","article-title":"Participant preferences for pharmacologic chronic pain treatment trial characteristics: an ACTTION adaptive choice-based conjoint study","volume":"17","author":"Smith","year":"2016","journal-title":"J Pain"},{"issue":"23","key":"10.1016\/j.jcf.2023.04.024_bib0016","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1212\/01.wnl.0000336652.05779.ea","article-title":"How redesigning AD clinical trials might increase study partners\u2019 willingness to participate","volume":"71","author":"Karlawish","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.024_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045803","article-title":"Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials","volume":"11","author":"Dobra","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcf.2023.04.024_bib0018","series-title":"Vol. 32, PharmacoEconomics","first-page":"883","article-title":"Discrete choice experiments in health economics: a review of the literature","author":"Clark","year":"2014"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.024_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete choice experiments in health economics: past, present and future","volume":"37","author":"Soekhai","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jcf.2023.04.024_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/002224379403100408","article-title":"Efficient experimental design with marketing research applications","volume":"31","author":"Kuhfeld","year":"1994","journal-title":"J Market Res"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.024_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.04.024_bib0022","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.6004\/jnccn.2010.0102","article-title":"Geographic proximity and racial disparities in cancer clinical trial participation","volume":"8","author":"Kanarek","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"year":"2000","series-title":"Finite Mixture Models","author":"McLachlan","key":"10.1016\/j.jcf.2023.04.024_bib0023"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.024_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Johnson","year":"2013","journal-title":"Value in Health [Internet]"},{"issue":"8","key":"10.1016\/j.jcf.2023.04.024_bib0025","article-title":"Discrete choice experiment to evaluate preferences of patients with cystic fibrosis among alternative treatment-related health outcomes: a protocol","volume":"9","author":"McLeod","year":"2019","journal-title":"BMJ Open [Internet]."},{"issue":"5","key":"10.1016\/j.jcf.2023.04.024_bib0026","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jcf.2019.06.011","article-title":"European CF Society (ECFS) Strategic Planning Task Force on \u2018Speeding up access to new 4 drugs for CF,\u2019 et\u00a0al. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery","volume":"18","author":"Davies","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.024_bib0027","first-page":"493","article-title":"Race and HIV clinical trial participation","volume":"102","author":"Defreitas","year":"2010","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.024_bib0028","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jcf.2021.03.021","article-title":"Guiding the rational design of patient-centred drug trials in cystic fibrosis: a Delphi study","volume":"20","author":"Dobra","year":"2021","journal-title":"J Cyst Fibros [Internet]"},{"key":"10.1016\/j.jcf.2023.04.024_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.578888","article-title":"Telemedicine in oncology: delivering on an overdue promise in the COVID-19 era","volume":"10","author":"West","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcf.2023.04.024_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/jocn.14785","article-title":"Cancer patients\u2019 perceptions of factors influencing their decisions on participation in clinical drug trials: A qualitative meta-synthesis","author":"Nielsen","year":"2019","journal-title":"J Clin Nurs"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.024_bib0031","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1740774510392257","article-title":"Personal benefit, or benefiting others? Deciding whether to take part in clinical trials","volume":"8","author":"Locock","year":"2011","journal-title":"Clin Trials: J Soc Clin Trials"},{"key":"10.1016\/j.jcf.2023.04.024_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2019.04.008","article-title":"Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials","author":"Dobra","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.024_bib0033","doi-asserted-by":"crossref","unstructured":"Dobra R, Davies G, Pike K, Strassle C, Allen L, Brendell R, et\u00a0al. Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)? 2021 Nov 1 [cited 2022 May 11];20(6):978\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33875366\/.","DOI":"10.1016\/j.jcf.2021.03.027"},{"key":"10.1016\/j.jcf.2023.04.024_bib0034","first-page":"209","volume":"16","author":"Kirwan","year":"2019"},{"key":"10.1016\/j.jcf.2023.04.024_bib0035","series-title":"Patient views on payment for trial participation","first-page":"PA3163","author":"Dobra","year":"2018"},{"issue":"4","key":"10.1016\/j.jcf.2023.04.024_bib0036","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcf.2017.02.012","article-title":"Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation","volume":"16","author":"Vandevanter","year":"2017","journal-title":"Journal of Cystic Fibrosis [Internet]"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.024_bib0037","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/heapol\/czn047","article-title":"How to do (or not to do) ... Designing a discrete choice experiment for application in a low-income country","volume":"24","author":"Mangham","year":"2009","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jcf.2023.04.024_bib0038","unstructured":"How Social Media Impacts Brand Marketing | Nielsen \u2013 Nielsen [Internet]. [cited 2020 Sep 3]. Available from: https:\/\/www.nielsen.com\/us\/en\/insights\/article\/2011\/how-social-media-impacts-brand-marketing\/."},{"key":"10.1016\/j.jcf.2023.04.024_bib0039","doi-asserted-by":"crossref","unstructured":"Marta-Pedroso C, Freitas H, Domingos T. Testing for the survey mode effect on contingent valuation data quality: a case study of web based versus in-person interviews. 2007;.","DOI":"10.1016\/j.ecolecon.2007.02.005"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:12:43Z","timestamp":1767240763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323001303"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.024","relation":{},"ISSN":["1569-1993"],"issn-type":[{"type":"print","value":"1569-1993"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A discrete choice experiment to quantify the influence of trial features on the decision to participate in cystic fibrosis trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}